StockNews.AI
ALNY
StockNews.AI
144 days

siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials

1. Alnylam leads with 79 siRNA clinical trials, indicating strong market position. 2. A total of 334 deals in siRNA sector reached $107 billion, revealing growth potential. 3. Metabolic disorder trials are the most prevalent, with Hepatitis B as a focus. 4. New patents in siRNA innovation are trending, especially from universities and research institutions. 5. Alnylam is a key player, alongside notable competitors and emerging startups.

8m saved
Insight
Article

FAQ

Why Bullish?

Alnylam’s leadership in clinical trials and strong deal activity suggests potential for growth. Historically, strong performers in biotech with high trial volumes often see incremental price increases.

How important is it?

The article discusses industry trends and Alnylam's position, indicating potential market movement.

Why Long Term?

The ongoing siRNA innovation and pipeline development will likely drive long-term growth. Established players like Alnylam typically benefit from sustained market interest over years.

Related Companies

ARWRSRNATHMO
Dublin, March 28, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: siRNA gene silencing" report has been added to ResearchAndMarkets.com's offering. In terms of deals, there have been 334 deals totaling US$107 billion in the siRNA gene silencing sector. The United States and Ireland stand out with two major M&A deals worth $54.9 billion. The highest deal volume was observed in 2023, while the highest deal value was seen in 2020. The slight decline in 2021, followed by a slight increase in 2022, may indicate market adjustments and strategic consolidations. The United States is the major geography for deals, with a deal value of US$54.9 billion and the highest deal volume since 2020. Alnylam Pharmaceuticals Inc leads the way in clinical trials for siRNA gene silencing drugs, with 79 trials, followed by Arrowhead Pharmaceuticals Inc with 48 trials. Metabolic disorders trials are the most prevalent, with Hepatitis B being the top indication. siRNA, or short interfering RNA, is a non-coding RNA sequence that can inhibit gene expression, making it a key component in various therapeutic innovations. While the discovery of siRNA for targeted therapies dates back over a decade, current efforts are focused on improving stability and targeted delivery. The gene silencing capabilities of siRNA have led to its widespread use in novel therapies, with a significant number of patents set to expire in the near future. Recent patent analysis shows a growing trend in siRNA innovation, with a particular focus on metabolic diseases, infectious diseases, neurological diseases, and cardiovascular diseases. The majority of patent activity is driven by universities and research institutions, with over 100 new entities filing patents in the past two years. The innovation landscape is primarily dominated by companies in Southeast Asia, particularly in China, Japan, and South Korea. Among publicly listed companies, leaders in siRNA gene silencing include Alnylam, Thermo Fisher (Revvity/Dharmacon), and Sirnaomics. Additionally, there are over 50 startups in this space, with Chinese companies like Suzhou Ribo Life Sciences and Gangzhou Ribo Bio leading the way. In the drug landscape, there are currently 799 siRNA gene silencing drugs in development, with a focus on oncology and metabolic disorders therapies. The most common route of administration is subcutaneous, and major players like Alnylam Pharmaceuticals Inc and Sirnaomics Ltd are leading the way in drug development, particularly in Phase I and Phase II trials. Key Highlights siRNA Gene Silencing report is a high-impact innovation area in the Pharma industry, with a growing number of patents being filed and a focus on new indications such as Oncology and Infectious diseases.Big pharma companies like Merck and co dominate the patent activity in Membrane protein targeting and modulation with a dip in new companies filing patents in recent years.Competitive intelligence shows that Alnylam leads in terms of portfolio size followed by Hanmi Science and Eli Lilly&Co. are among the leaders with strong innovation portfolios in siRNA gene silencing.Startups like Suzhou Ribo Life Sciences, Ractigen and Curigin are leading in terms of innovation impact and focus in the siRNA gene silencing.The drug landscape for siRNA gene silencing is dominated by innovator drugs, with a focus on Oncology and Metabolic disorders, and major players like Alnylam Pharmaceuticals Inc and sirnaomics Ltd leading in drug development.Clinical trials in siRNA gene silencing are dominated by Metabolic disorders trials, with the Alnylam Pharmaceuticals Inc leading in the number of trials. Scope Innovation Insights: innovation examples by each use cases segment of various sectors to present key trends.Key player: This represents a sample list of key players in each use case highlighted in the report.Startups: This represents a sample list of emerging starups in each use case highlighted in the report.University: This represents a sample list of leading universities in each use case highlighted in the report. Reasons to Buy Drive Innovation with Our siRNA Gene Silencing Report:Emerging technologies like siRNA gene silencing are revolutionizing healthcare, and staying ahead requires actionable insights. Our report offers comprehensive analysis of patents, drug pipelines, clinical trials, and market dynamics, empowering strategic planning and R&D decisions. Stay informed on regulatory changes and clinical advancements critical for navigating the evolving healthcare landscape. Identify investment opportunities through detailed financial deal and funding trend analyses. Whether you're a pharmaceutical leader, biotech innovator, or academic researcher, this report delivers essential competitive intelligence to guide data-driven decisions and ensure you remain at the forefront of gene silencing innovation. Key Topics Covered:1. Innovation Insights1.1 Innovation radar1.2 Innovation s-curve1.3 Innovation deep dive1.4 Innovation deep dive - trending indications1.5 Top companies Based on portfolio strength and temporal indicators2. Competitive Insights2.1 Key innovation leaders - big pharma2.2.Key innovators - startups and small biotech2.3 Key innovations - Universities and research institutions2.4 Most cited patents2.5 Insights from AI hub 3.Market Insights3.1 Drugs3.1.1 Key Players3.1.2 Route of administration & drug type3.1.3 Top therapy area & indication3.2 Clinical Trials3.2.1 Key Sponsors3.2.2 Key development stages3.3 Deals3.3.1. Key Acquirers3.3.2 Deal type distribution3.3.3 Geographical distributionA selection of companies mentioned in this report includes, but is not limited to: Alnylam Pharmaceuticals IncSirnaomics LtdNovo Nordisk ASSuzhou Ribo Life Sciences Co LtdShanghai Argo Pharmaceutical Co LtdOliX Pharmaceuticals IncArrowhead Pharmaceuticals IncQuark Pharmaceuticals IncSilence Therapeutics PlcPhio Pharmaceuticals CorpArbutus Biopharma CorpArgonaute RNA LtdSanegene Bio USA IncRona Therapeutics IncsiRNAgen Therapeutics Corpe-Therapeutics PlcSylentis SAU Risen(Shanghai) Pharma Tech Co LtdSirius Therapeutics IncNovartis AGAdhera Therapeutics IncAlys Pharmaceuticals IncEli Lilly and CoSynerk IncJivana Biotechnology Inc For more information about this report visit https://www.researchandmarkets.com/r/22dful About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Related News